GlassScriptPhysician profile
Eric D Laviaddin
NPI 1245546860
$3,654.79
in general payments reported to CMS, 2019-2025
21 companies · $588 in 2025
The $588 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $593 · 2022: $1,300 · 2023: $882 · 2024: $292 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,719.49 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,029.63 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $390.47 | 2022-2025 | |
| Redhill Biopharma INC. | $318.69 | 2021-2023 | Movantik, Aemcolo, Talicia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.76 | 2021-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $236.13 | 2021 | |
| Lilly USA, LLC | $232.54 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $189.47 | 2021-2024 | Breztri, Airsupra |
| Pfizer INC. | $184.87 | 2021-2025 | |
| Abbvie INC. | $127.27 | 2021-2022 | |
| Abbott Laboratories | $114.22 | 2022-2023 | Freestyle Libre 2 |
| Novo Nordisk INC | $108.06 | 2022-2024 | Ozempic, Rybelsus |
| Mannkind Corporation | $107.20 | 2025 | |
| Merck Sharp & Dohme LLC | $54.68 | 2023 | Belsomra |
| Amgen INC. | $45.05 | 2023-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $38.75 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $36.03 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $33.72 | 2025 | |
| Mycovia Pharmaceuticals, INC. | $30.32 | 2023 | Vivjoa |
| Phathom Pharmaceuticals, INC. | $29.28 | 2025 | Voquezna |
| Phadia US INC. | $25.67 | 2021 | |
| Cranial Technologies, INC | $22.98 | 2024 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Laviaddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.